Kallio-Kujala , I J , Bennett , R C , Raekallio , M R , Yatkin , E , Meierjohann , A , Savontaus , E , Scheinin , M , Spillmann , T & Vainio , O M 2018 , ' Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a glibenclamide-induced canine hypoglycaemia model ' , Veterinary Journal , vol. 242 , pp. 33-38 . https://doi.org/10.1016/j.tvjl.2018.09.012
Title: | Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a glibenclamide-induced canine hypoglycaemia model |
Author: | Kallio-Kujala, I. J.; Bennett, R. C.; Raekallio, M. R.; Yatkin, E.; Meierjohann, A.; Savontaus, E.; Scheinin, M.; Spillmann, T.; Vainio, O. M. |
Contributor organization: | Small Animal Hospital Equine and Small Animal Medicine Faculty of Veterinary Medicine Marja Raekallio / Principal Investigator Thomas Spillmann / Principal Investigator Outi Vainio / Principal Investigator Research Centre for Animal Welfare DAPHNE - Developing Assessment Practices in Higher Education Teachers' Academy |
Date: | 2018-12 |
Language: | eng |
Number of pages: | 6 |
Belongs to series: | Veterinary Journal |
ISSN: | 1090-0233 |
DOI: | https://doi.org/10.1016/j.tvjl.2018.09.012 |
URI: | http://hdl.handle.net/10138/294741 |
Abstract: | The commonly used sedative alpha(2)-adrenoceptor agonist dexmedetomidine has adverse cardiovascular effects in dogs that can be prevented by concomitant administration of the peripherally acting alpha(2)-adrenoceptor antagonist MK-467. An ancillary effect of dexmedetomidine is to decrease insulin release from the pancreas, whereas MK-467 stimulates insulin release. This study assessed the effects of co-administered dexmedetomidine and MK-467 in a canine glibenclamide-induced hypoglycaemia model. In a randomised, cross-over experiment, eight beagle dogs received five intravenous treatments, comprising two administrations of saline, with dexmedetomidine or dexmedetomidine and MK-467, and three administrations of glibenclamide, with saline, dexmedetomidine or dexmedetomidine and MK-467. Plasma concentrations of glucose, lactate, insulin, glucagon and the test drugs were monitored. Administration of glibenclamide significantly increased insulin secretion and decreased blood glucose concentrations. Dexmedetomidine counteracted glibenclamide-evoked hypoglycaemia. This was opposed by the alpha(2)-adrenoceptor antagonist MK-467, but the glibenclamide-evoked hypoglycaemia was not potentiated by co-administration of dexmedetomidine and MK-467. None of the dogs developed uncontrolled hypoglycaemia. Thus, the combination of dexmedetomidine and MK-467 appeared to be safe in this canine hypoglycaemia model. Nevertheless, when MK-467 is used to alleviate the undesired cardiovascular effects of alpha(2)-adrenoceptor agonists in dogs, it should be used with caution in animals at risk for hypoglycaemia because of its insulin-releasing and hypoglycaemic effects. (C) 2018 The Author(s). Published by Elsevier Ltd. |
Subject: |
Canine
Dexmedetomidine Glibenclamide Hypoglycaemia MK-467 ALPHA(2)-ADRENERGIC RECEPTOR ANTAGONIST INTRAVENOUS DEXMEDETOMIDINE MEDETOMIDINE PHARMACOKINETICS CARDIOPULMONARY SECRETION LACTATE DOG 413 Veterinary science |
Peer reviewed: | Yes |
Rights: | cc_by |
Usage restriction: | openAccess |
Self-archived version: | publishedVersion |
Total number of downloads: Loading...
Files | Size | Format | View |
---|---|---|---|
vetj1_s2.0_S1090023318305835_main.pdf | 888.4Kb |
View/ |